Apple's Cook Heads ...
Health Care: Drugs
OncoGenex Pharmaceuticals Inc. (OGXI: NASDAQ)
$10.43 -0.07 | -0.67%
05/20/13 - 04:00 PM ET
53.69K / 68.30K
Vol / Avg. Vol:10.49 / 10.50
Open / Prev. Close:10.38 - 10.57
Today's Range:9.16 - 14.99
52 Wk Range:-19.97%
Performance YTD:TheStreet Rating:
Portfolios with OGXI
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- UserLong Term Stock Picks
- Contributor10 Health-Care Stocks Outpe...
- Contributor9 Health Care Stocks With 1...
- Contributor10 Pharma Stocks With 100% ...
- Contributor10 Biotech Stocks Expected ...
- UserDouble QE2
- Contributor10 Stocks Expected to Doubl...
- Contributor10 Small-Cap Stocks With No...
- UserSUPRATRADE Top 10 Best-Rate...
Latest OGXI Headlines from TheStreet
- OncoGenex Pharmaceuticals Becomes Oversold (OGXI) 05.01.13 | 12:05 pm
- OncoGenex Stock Gaps Down On Today's Open (OGXI) 03.16.12 | 10:03 am
- 10 Health-Care Stocks Outperforming the Index 06.07.11 | 01:06 pm
- 9 Health Care Stocks With 100% Buy Ratings 05.05.11 | 04:05 pm
- Biotech Stock Mailbag: Exact Sciences 02.25.11 | 07:02 am
- BIO CEO Conference Live Blog 02.14.11 | 02:02 pm
- 10 Biotech Stocks Expected to at Least Double 10.19.10 | 06:10 am
- 10 Stocks Expected to Double Amid QE2 10.11.10 | 08:10 am
- 10 Small-Cap Stocks With No 'Sell' Ratings 10.04.10 | 06:10 am
- OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript 05.10.10 | 02:05 am
Press Releases for OGXI
- OncoGenex Announces Plans For The Initiation Of The Spruceâ¿¢ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer - PR Newswire 04.11.13 | 08:04 am
- OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference - PR Newswire 03.28.13 | 04:03 pm
- OncoGenex To Webcast Update On Clinical Development Program And Discussion Of Fourth Quarter And Full Year 2012 Financial Results On Thursday, March 7, 2013 - PR Newswire 02.28.13 | 04:02 pm
- OncoGenex Announces Plans For The Initiation Of The Borealis-2 Clinical Trial Evaluating OGX-427 In Combination With Second-Line Therapy For Bladder Cancer - PR Newswire 02.12.13 | 08:02 am
- OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences - PR Newswire 02.05.13 | 04:02 pm
- OncoGenex Announces Initiation Of Randomized Phase 2 "PACIFIC" Study Of OGX-427 In Combination With Zytiga® In Men With Metastatic Castrate-Resistant Prostate Cancer - PR Newswire 12.19.12 | 09:12 am
- OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference - PR Newswire 11.09.12 | 06:11 am
- OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study - PR Newswire 11.06.12 | 09:11 am
- OncoGenex To Webcast Discussion Of Third Quarter 2012 Financial Results On Thursday, November 8, 2012 - PR Newswire 10.30.12 | 04:10 pm
- OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer - PR Newswire 09.27.12 | 04:09 pm
Partner Headlines for OGXI
- 5 Pharmaceutical Companies With Insider Buying During August 14-16 - Seeking Alpha 08.19.12 | 05:08 am
- UNVEILED: New Equity Analyst Coverage Shared With Public Investors - Wall St. Cheat Sheet 06.18.12 | 03:06 am
- Keeping An Eye On Isis - Seeking Alpha 01.13.12 | 07:01 pm
- Equity X factor often spells exasperation - Financial Times 12.10.10 | 11:12 pm
- Predictions for Biotech Data Heading to ASCO - Seeking Alpha 06.02.10 | 03:06 am
- Teva Expands Oncology Pipeline - Analyst Blog - Zacks 04.14.10 | 11:04 am
- Isis Loss Widens - Analyst Blog - Zacks 03.03.10 | 10:03 am
